afatinib in patients with uncommon egfr mutations
Published 6 years ago • 417 plays • Length 4:06Download video MP4
Download video MP3
Similar videos
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:25
dr. giorgio scagliotti discusses afatinib in patients with egfr mutation
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
17:27
how, when, and where to utilize erlotinib, afatinib, and gefitinib in egfr positive nsclc
-
1:35
dr. bunn discusses afatinib for patients with egfr mutation
-
1:33:47
oncology cancer treatment update - 23 aug 2024
-
8:47
study of 693 nsclc patients treated with afatinib
-
1:41
egfr mutations in patients with lung cancer
-
6:28
sequential treatment with afatinib and osimertinib in patients with egfr mutation-positive nsclc
-
6:43
sequential afatinib and osimertinib in egfr mutation-positive nsclc patients: updated results
-
4:09
frontline afatinib in egfr-mutant nsclc
-
0:37
response to systemic anti-cancer therapy in uncommon egfr mutations
-
1:25
dr. chachoua on afatinib for exon 19 mutation in lung cancer
-
2:26
egfr mutations in nsclc
-
0:58
the activity of afatinib in lung cancer
-
1:56
what targeted therapies are used for people with the egfr mutation?
-
1:13
identification of egfr mutations impact overall prognosis in lung cancers